These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 21480817)

  • 21. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.
    Díaz-Molina B; Tavira B; Lambert JL; Bernardo MJ; Alvarez V; Coto E
    Transplant Proc; 2012 Nov; 44(9):2635-8. PubMed ID: 23146479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of CYP3A4*22 and CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients.
    Ebid AIM; Ismail DA; Lotfy NM; Mahmoud MA; ELSharkawy M
    J Clin Pharm Ther; 2022 Dec; 47(12):2255-2263. PubMed ID: 36379901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation.
    Yang TH; Chen YK; Xue F; Han LZ; Shen CH; Zhou T; Luo Y; Zhang JJ; Xia Q
    Int J Clin Pract Suppl; 2015 May; (183):53-62. PubMed ID: 26176181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients.
    Lesche D; Sigurdardottir V; Setoud R; Oberhänsli M; Carrel T; Fiedler GM; Largiadèr CR; Mohacsi P; Sistonen J
    Ther Drug Monit; 2014 Dec; 36(6):710-5. PubMed ID: 24739669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of CPY3A5 Genetic Polymorphisms on the Pharmacokinetics of Extendedrelease and Immediate-release Tacrolimus Formulations in Renal Transplant Recipients: A Systematic Review and Meta-analysis.
    Xie Q; Xiang Q; Liu Z; Mu G; Zhou S; Zhang Z; Ma L; Cui Y
    Curr Drug Metab; 2021; 22(10):758-771. PubMed ID: 34525930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching Immunosuppression From Cyclosporine to Tacrolimus in Kidney Transplant Recipients Based on CYP3A5 Genotyping.
    Wang X; Yang Y; Liu Z; Xiao C; Gao L; Zhang W; Zhang W; Wang Z
    Ther Drug Monit; 2019 Feb; 41(1):97-101. PubMed ID: 30520827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of CYP3A5 polymorphism on tacrolimus maintenance doses and serum levels after renal transplantation: age dependency and pharmacological interaction with steroids.
    Ferraris JR; Argibay PF; Costa L; Jimenez G; Coccia PA; Ghezzi LF; Ferraris V; Belloso WH; Redal MA; Larriba JM
    Pediatr Transplant; 2011 Aug; 15(5):525-32. PubMed ID: 21711429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of cytochrome P450 3A5 polymorphisms on viral infection incidence in kidney transplant patients treated with tacrolimus.
    Hattori Y; Tanaka H; Teranishi J; Ishida H; Makiyama K; Miyajima E; Noguchi K; Kubota Y
    Transplant Proc; 2014; 46(2):570-3. PubMed ID: 24656015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Gayle AA; Nobori T; Katayama N; Okuda M
    Ther Drug Monit; 2015 Oct; 37(5):581-8. PubMed ID: 25565672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients.
    Liu J; Ouyang Y; Chen D; Yao B; Lin D; Li Z; Zang Y; Liu H; Fu X
    Int Immunopharmacol; 2018 Apr; 57():18-24. PubMed ID: 29454235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living-donor Egyptian kidney transplanted patients.
    Wanas H; Kamel MH; William EA; Fayad T; Abdelfattah ME; Elbadawy HM; Mikhael ES
    J Clin Lab Anal; 2023 Oct; 37(19-20):e24969. PubMed ID: 37789683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tacrolimus Therapeutic Drug Monitoring in Stable Kidney Transplantation and Individuation of CYP3A5 Genotype.
    Allegri L; Baldan F; Vallone C; Tulissi P; Gropuzzo M; Canelles MF; Righi E; Adani GL; Baccarani U; Montanaro D; Risaliti A; Damante G; Baraldo M
    Transplant Proc; 2019 Nov; 51(9):2917-2920. PubMed ID: 31711577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Genetic Variants in CYP3A4, CYP3A5, CYP2C8, and CYP2C19 with Tacrolimus Pharmacokinetics in Renal Transplant Recipients.
    Wang Z; Zheng M; Yang H; Han Z; Tao J; Chen H; Sun L; Guo M; Wang L; Tan R; Wei JF; Gu M
    Curr Drug Metab; 2019; 20(7):609-618. PubMed ID: 31244435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.
    Bruckmueller H; Werk AN; Renders L; Feldkamp T; Tepel M; Borst C; Caliebe A; Kunzendorf U; Cascorbi I
    Ther Drug Monit; 2015 Jun; 37(3):288-95. PubMed ID: 25271728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of CYP3A5 Genomic Variances and Their Impact on Tacrolimus Dosing Requirements among Kidney Transplant Recipients in Eastern North Carolina.
    Maldonado AQ; Asempa T; Hudson S; Rebellato LM
    Pharmacotherapy; 2017 Sep; 37(9):1081-1088. PubMed ID: 28605053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation.
    Capron A; Mourad M; De Meyer M; De Pauw L; Eddour DC; Latinne D; Elens L; Haufroid V; Wallemacq P
    Pharmacogenomics; 2010 May; 11(5):703-14. PubMed ID: 20415563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients.
    Liu MZ; He HY; Zhang YL; Hu YF; He FZ; Luo JQ; Luo ZY; Chen XP; Liu ZQ; Zhou HH; Shao MJ; Ming YZ; Xin HW; Zhang W
    Acta Pharmacol Sin; 2017 Mar; 38(3):415-423. PubMed ID: 28112181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation.
    Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Habuchi T; Satoh S; Miura M
    Int J Mol Sci; 2015 Jan; 16(1):1840-54. PubMed ID: 25594874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The distribution of genetic polymorphism of CYP3A5, CYP3A4 and ABCB1 in patients subjected to renal transplantation.
    Vavić N; Rančić N; Cikota-Aleksić B; Magić Z; Cimeša J; Obrenčević K; Radojević M; Mikov M; Dragojević-Simić V
    Vojnosanit Pregl; 2016 Jul; 73(7):663-7. PubMed ID: 29314799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.